Cargando…
Dacarbazine nanoparticle topical delivery system for the treatment of melanoma
Dacarbazine (DZ) is poorly soluble in water with the short half-life in blood circulation, low rate of response with the toxic effect which ultimately limits its utilization of the treatment of skin cancer. In view of this background current study was designed for development of dacarbazine laden na...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705606/ https://www.ncbi.nlm.nih.gov/pubmed/29184162 http://dx.doi.org/10.1038/s41598-017-16878-1 |
_version_ | 1783282052351655936 |
---|---|
author | Hafeez, Abdul Kazmi, Imran |
author_facet | Hafeez, Abdul Kazmi, Imran |
author_sort | Hafeez, Abdul |
collection | PubMed |
description | Dacarbazine (DZ) is poorly soluble in water with the short half-life in blood circulation, low rate of response with the toxic effect which ultimately limits its utilization of the treatment of skin cancer. In view of this background current study was designed for development of dacarbazine laden nanoparticle (DZNP) and dacarbazine laden nanocream (DZNC) topical delivery system for the treatment of melanoma. Firstly DZNP was prepared. By using DZNP its cream formulation prepared for topic drug delivery for melanoma. Dacarbazine nanoparticle and its cream were evaluated for morphology, drug load capacity, efficiency of nanoencapsulation and size of particle and zeta potential, Transmission Electron Microscopy (TEM), determination of pH, spreadability and viscosity, in vitro drug release capacity and its cytotoxic potential. The particle size of DZNP and DZNC was 16.3 ± 8.1 nm and 16.9 ± 7.8 nm respectively. pH value and spreadability of nanoparticle cream were found to be 6.7 ± 0.14 g cm/sec and 55.23 ± 3.13 g cm/sec respectively. Nanoencapsulation efficiency and Drug loading capacity were 67.4 ± 3.5% and 6.73 mg/10 mg respectively. IC50 of dacarbazine nanoparticle was 0.19 mg/ml while it was 0.63 mg/ml for nanoparticle cream. It can be concluded that DZNP and its cream can be effectively used as a topical formulation for the treatment of melanoma. |
format | Online Article Text |
id | pubmed-5705606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-57056062017-12-05 Dacarbazine nanoparticle topical delivery system for the treatment of melanoma Hafeez, Abdul Kazmi, Imran Sci Rep Article Dacarbazine (DZ) is poorly soluble in water with the short half-life in blood circulation, low rate of response with the toxic effect which ultimately limits its utilization of the treatment of skin cancer. In view of this background current study was designed for development of dacarbazine laden nanoparticle (DZNP) and dacarbazine laden nanocream (DZNC) topical delivery system for the treatment of melanoma. Firstly DZNP was prepared. By using DZNP its cream formulation prepared for topic drug delivery for melanoma. Dacarbazine nanoparticle and its cream were evaluated for morphology, drug load capacity, efficiency of nanoencapsulation and size of particle and zeta potential, Transmission Electron Microscopy (TEM), determination of pH, spreadability and viscosity, in vitro drug release capacity and its cytotoxic potential. The particle size of DZNP and DZNC was 16.3 ± 8.1 nm and 16.9 ± 7.8 nm respectively. pH value and spreadability of nanoparticle cream were found to be 6.7 ± 0.14 g cm/sec and 55.23 ± 3.13 g cm/sec respectively. Nanoencapsulation efficiency and Drug loading capacity were 67.4 ± 3.5% and 6.73 mg/10 mg respectively. IC50 of dacarbazine nanoparticle was 0.19 mg/ml while it was 0.63 mg/ml for nanoparticle cream. It can be concluded that DZNP and its cream can be effectively used as a topical formulation for the treatment of melanoma. Nature Publishing Group UK 2017-11-28 /pmc/articles/PMC5705606/ /pubmed/29184162 http://dx.doi.org/10.1038/s41598-017-16878-1 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Hafeez, Abdul Kazmi, Imran Dacarbazine nanoparticle topical delivery system for the treatment of melanoma |
title | Dacarbazine nanoparticle topical delivery system for the treatment of melanoma |
title_full | Dacarbazine nanoparticle topical delivery system for the treatment of melanoma |
title_fullStr | Dacarbazine nanoparticle topical delivery system for the treatment of melanoma |
title_full_unstemmed | Dacarbazine nanoparticle topical delivery system for the treatment of melanoma |
title_short | Dacarbazine nanoparticle topical delivery system for the treatment of melanoma |
title_sort | dacarbazine nanoparticle topical delivery system for the treatment of melanoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705606/ https://www.ncbi.nlm.nih.gov/pubmed/29184162 http://dx.doi.org/10.1038/s41598-017-16878-1 |
work_keys_str_mv | AT hafeezabdul dacarbazinenanoparticletopicaldeliverysystemforthetreatmentofmelanoma AT kazmiimran dacarbazinenanoparticletopicaldeliverysystemforthetreatmentofmelanoma |